Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 14/20 | 0.61 |
| ▸ | RAB9A | P51151 | 12/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.58 |
| ▸ | MEN1 | O00255 | 8/20 | 0.58 |
| ▸ | GAA | P10253 | 4/20 | 0.58 |
| ▸ | MPO | P05164 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 3/20 | 0.54 |
| ▸ | KDR | P35968 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Budralazine SCHEMBL3499915 | 1.00 | NPC1 (0.61) | NPC1RAB9AKMT2AMEN1GAA | |
| Budralazine SCHEMBL3499913 | 1.00 | NPC1 (0.61) | NPC1RAB9AKMT2AMEN1GAA | |
| Budralazine SCHEMBL1650586 | 0.97 | NPC1 (0.58) | NPC1RAB9AKMT2AMEN1GAA | |
| SCHEMBL13286648 | 0.84 | NPC1 (0.68) | NPC1RAB9AKMT2AMEN1GAA | |
| SCHEMBL13286654 | 0.79 | NPC1 (0.62) | NPC1RAB9AKMT2AMEN1GAA | |
| SCHEMBL13286718 | 0.79 | NPC1 (0.64) | NPC1RAB9AKMT2AMEN1GAA | |
| SCHEMBL13286707 | 0.79 | NPC1 (0.62) | NPC1RAB9AKMT2AMEN1GAA | |
| SCHEMBL13286661 | 0.79 | RAB9A (0.82) | NPC1RAB9AKMT2AMEN1GAA | |
| SCHEMBL13286655 | 0.78 | NPC1 (0.61) | NPC1RAB9AKMT2AMEN1GAA | |
| SCHEMBL13286723 | 0.77 | NPC1 (0.60) | NPC1RAB9AKMT2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1727 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118773-A1 | CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR | THERACOSBIO, LLC | 2018-05-03 | — | — | US | claimed |
| US-9498477-B2 | Compositions and uses thereof to ameliorate pain | PURDUE RESEARCH FOUNDATION (US) | 2016-11-22 | — | — | US | claimed |
| US-20160175379-A1 | COMBINATION THERAPY FOR THE TREATMENT OF ISCHEMIA-REPERFUSION INJURY | STEALTH BIO THERAPEUTICS CORP (MC) | 2016-06-23 | — | — | US | claimed |
| US-20150352094-A1 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | CATABASIS PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | claimed |
| EP-2941252-A2 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | Catabasis Pharmaceuticals, Inc. (US) | 2015-11-11 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20150112061-A1 | COMPOSITIONS AND USES THEREOF TO AMELIORATE PAIN | PURDUE RESEARCH FOUNDATION (US) | 2015-04-23 | — | — | US | claimed |
| WO-2015023680-A1 | COMBINATION THERAPY FOR THE TREATMENT OF ISCHEMIA-REPERFUSION INJURY | STEALTH PEPTIDES INTERNATIONAL, INC. (MC) | 2015-02-19 | — | — | WO | claimed |
| WO-2014107730-A2 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | WO | claimed |
| US-20130345424-A1 | COMPOSITIONS AND USES THEREOF TO AMELIORATE PAIN | PURDUE RESEARCH FOUNDATION (US) | 2013-12-26 | — | — | US | claimed |
| WO-2002034303-A1 | METHODS OF TREATING VASCULAR DISEASES CHARACTERIZED BY NITRIC OXIDE INSUFFICIENCY | NITROMED, INC. (US) | 2002-05-02 | — | — | WO | claimed |
| WO-2001035961-A1 | METHODS OF TREATING VASCULAR DISEASES CHARACTERIZED BY NITRIC OXIDE INSUFFICIENCY | NITROMED, INC. (US) | 2001-05-25 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| WO-2001017528-A1 | METHODS OF TREATING AND PREVENTING CONGESTIVE HEART FAILURE WITH HYDRALAZINE COMPOUNDS AND ISOSORBIDE DINITRATE OR ISOSORBIDE MONONITRATE | NITROMED, INC. (US) | 2001-03-15 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| CN-1276246-A | Process for preparing medicines with no or low loxic by-effect on gastrointestinal system | WANG XIAO (CN) | 2000-12-13 | — | — | CN | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160175379-A1 | COMBINATION THERAPY FOR THE TREATMENT OF ISCHEMIA-REPERFUSION INJURY | TNNI3, FABP3, TNNT2 | NPC1 3893/4885RAB9A 2613/4885KMT2A 4660/4885 |
| US-20150112061-A1 | COMPOSITIONS AND USES THEREOF TO AMELIORATE PAIN | ACHE, GPX4, COX15 | NPC1 2280/4885RAB9A 3855/4885KMT2A 3018/4885 |
| US-20150352094-A1 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | NAMPT, NNT, FASN | NPC1 32/4885RAB9A 1800/4885KMT2A 3150/4885 |
| US-20130345424-A1 | COMPOSITIONS AND USES THEREOF TO AMELIORATE PAIN | ACHE, GPX4, COX15 | NPC1 2092/4885RAB9A 3786/4885KMT2A 2847/4885 |
| US-20180118773-A1 | CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR | SLC5A2, SLC5A1, SLC2A4 | NPC1 105/4885RAB9A 2033/4885KMT2A 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.